Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2011

View Archived Issues

Updated data disclosed from RADIANT-2 and -3 trials of everolimus in neuroendocrine tumors

PEP-02 shows clinical benefit in pancreatic and gastric cancer

Targeting of CD44 by miRNA-34a suppresses regeneration and metastatic potential of prostate CSCs

New antiviral agents claimed with activity against HAdV-37

European scientists develop new compounds targeting negative-sense ssRNA viruses

Dasatinib is not active in previously treated metastatic colorectal cancer

Antibodies against Glo-3A as a biomarker of celiac disease

Merck & Co. discloses new orexin OX2 receptor antagonists

Novel flourine-containing oligopeptides presented by Harvard College

Novartis develops novel PI3K-alpha inhibitors

Bristol-Myers Squibb offers update on fourth quarter 2010

New inhibitors claimed of RAC-alpha serine/threonine-protein kinase phosphorylation

Hutchison MediPharma begins phase I trial of fruquintinib in China

Oragenics plans second phase I trial of SMaRT replacement therapy

Phase IIb follow-up data show efficacy of KUR-111 in bone regeneration

Alexion acquires Taligen Therapeutics and expands portfolio

FDA sets PDUFA date for Transcept's Intermezzo NDA resubmission

Eisai receives complete response letter regarding NDA for new AcipHex formulation

EMA confirms eligibility of Omeros' OMS-103HP for centralized marketing application

BioMarin begins phase III trial of N-acetylgalactosamine 6-sulfatase in MPS IVA

Enrollment begins in phase II CP-4126 trial in gemcitabine-refractory pancreatic cancer

ToleroMune cat allergy T-cell vaccine shows efficacy in phase II trial

Lixisenatide demonstrates noninferiority to exenatide in phase III GetGoal-X trial

Rockwell Medical secures participation of two U.S. dialysis companies in phase III SFP trials

FDA requests additional trial of Contrave

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...